Premium
Going back to class I: MHC and immunotherapies for childhood cancer
Author(s) -
Haworth Kellie B.,
Leddon Jennifer L.,
Chen ChunYu,
Horwitz Edwin M.,
Mackall Crystal L.,
Cripe Timothy P.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25359
Subject(s) - medicine , mhc class i , immunotherapy , blood cancer , cancer immunotherapy , cancer , clinical trial , pediatric cancer , major histocompatibility complex , childhood cancer , immunology , oncology , antigen
After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T‐cell versus NK‐mediated therapies, and strategies to reverse or circumvent MHC down‐regulation.Pediatr Blood Cancer 2015;62:571–576. © 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom